We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > COM701

News List

Compugen Expands Collaboration with Bristol Myers Squibb in COM701, Opdivo Study americanpharmaceuticalreview
February 26, 2021
Compugen announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study ...
Compugen Announces Triple Combination Study to Evaluate COM701, Opdivo, TIGIT Inhibitor americanpharmaceuticalreview
March 09, 2020
Compugen announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody ...
Compugen Announces First Patient Dosed with COM701 americanpharmaceuticalreview
September 10, 2018
Compugen announced the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG.
FDA demand puts Compugen’s solid tumor checkpoint trial on ice fiercepharma
April 28, 2018
The FDA has temporarily blocked Compugen’s plans to start a phase 1 trial of PVRIG-targeting cancer drug COM701.